Safety and Efficacy of Neoantigen-Based Personalized Immunotherapy as Consolidation Therapy After Standard Adjuvant Treatment in Resectable Stage III Colorectal Cancer or Non-Small Cell Lung Cancer

Inclusion criteria

• ✓. Age ≥ 18 years and ≤ 80 years;
• ✓. Voluntarily signed written informed consent;
• ✓. Agreed to provide tumor tissue and whole blood for sequencing; or able to supply raw gene sequencing data required for tumor neoantigen analysis and design of personalized anti-tumor neoantigen injection, including whole-exome sequencing data of tumor tissue, transcriptome sequencing data, and whole-exome sequencing data of peripheral blood;
• ✓. Patients with pathologically confirmed, clinically diagnosed Stage III resectable colorectal cancer or non-small cell lung cancer;
• ✓. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;
• ✓. Underwent radical resection of lesions;
• ✓. Received postoperative adjuvant therapy in accordance with standard guideline-recommended regimens, completed the full guideline-recommended treatment cycles, and no new lesions were detected on imaging examinations;
• ✓. Complete imaging records must be available within 1 week prior to initiation of personalized immunotherapy, including but not limited to whole-body PET-CT and brain MRI. If whole-body PET-CT is not feasible, chest CT, contrast-enhanced abdominal CT, or bone ECT is required;

Exclusion criteria